Momenta Pharmaceuticals has dosed the first subject in a Phase I/II clinical trial of M254 for the treatment of Immune Thrombocytopenic Purpura (ITP), a rare autoimmune disease that results in excessive bruising and bleeding.

M254 is a hypersialylated human immunoglobulin G that contains improved tetra-sialylation.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The four-part trial features a placebo-controlled, randomised double-blinded cross-over design and is expected to enrol 65 healthy subjects and patients with ITP.

The trial is designed to examine the safety, efficacy, pharmacokinetics, and pharmacodynamics of intravenous (IV) M254 in comparison with intravenous immunoglobulin G(IVIg).

Parts A and B of the trial will feature double-blind, single ascending dose cohort design and will include healthy subjects and ITP patients respectively.

“We believe M254 has the potential to be a significantly better option for patients than conventional IVIg.”

Part C of the trial involves the administration of M254 or IVIg in a cross-over dosing design, while Part D will see patients with ITP treated with multiple doses of M254.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The trial’s primary efficacy objective is an assessment of platelet response.

Momenta Pharmaceuticals Development senior vice-president and chief medical officer Santiago Arroyo said: “We believe M254 has the potential to be a significantly better option for patients than conventional IVIg.

“Our aim for this study is to show clinically what we have observed in extensive preclinical models, which is that hypersialylated IgG is substantially more potent than intravenous immunoglobulin G (IVIg) in ITP and other inflammatory disorders.

“We look forward to obtaining initial clinical data in the first half of 2020.”

Results from preclinical studies of ITP and other inflammatory diseases showed that M254 increased the potency of patients up to ten times more than those treated with conventional IVIg.